Integrating Pharmacogenomics into Patient Care

We have learned through many years of research that genes play a role in how the body responds to medications. The GenoRx Program uses Pharmacogenomics, or PGx, is the study of how an individual's genetic makeup can play a role in the body's response to medications. Over the past 10 years, the extensive findings from clinical trials, in addition to translational discoveries and implementation, have demonstrated that PGx-guided prescribing can improve medication safety, shorten trial-and-error periods, and increase therapy adherence to achieve optimal clinical outcomes. To date, there are 27 published Level A guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) that provides prescribing guidance on 90+ medications across various therapeutic categories.

Where PGx has the Greatest Clinical Impact

PGx is most relevant where drug response variability is high, therapeutic windows are narrow, or the consequences of treatment failure are severe.  

    • Behavioral Health: antidepressants, anxiolytics with genes CYP2C19, CYP2D6
    • Cardiology: antiplatelet, statin, anticoagulant with genes CYP2C19, SLCO1B1, VKORC1
    • Oncology: chemotherapy with genes DPYD, TPMT, NUDT15, UGT1A1
    • Pain management: opioids, NSAIDs with genes CYP2D6, CYP2C9
    • Neurology: antiepileptics with genes HLA-A, HLA-B Primary care & polypharmacy: complex medication regimens, high-risk elderly patients

Test coverage is strongest when PGx testing is tied to a specific prescribing decision involving a drug-gene pair supported by CPIC Level A guideline. Click hereto see the full medication list.

Download Brochure

No items found.

“Pharmacogenomics is a fascinating field and incredibly necessary and important. The results of my test directly impacted my health. Now I can make much more informed choices about medications and can simply avoid likely medication problems that this test identified. My test results validate my own experience with various classes of medications which I have had negative reactions to over many years. I wish I’d had this data 20 or 30 years ago! I would have been able to prevent some serious problems. This is such an important field, and the information will help so many people avoid unnecessary suffering.”

Esther F

Providence Patient

Many patients are surprised to learn physicians can test their DNA to assess how the patient’s metabolism affects medication safety and effectiveness. “As we have piloted this in our primary care office, the impact on patient care reinforces the utility of easy access for testing. We have focused on treatment of depression and hyperlipidemia, and medication changes have been instituted as a result of our findings."

Dr. Devora Cohen

Santa Monica Family Physician

Learn more

Stay up to date on our research by following some of our primary researchers:

Bill Wright, PhD

Selected Works
  • Vice President of Health Innovation Research, Providence

Carlo Bifulco, MD

Selected Works
  • Member and Director, Translational Molecular Pathology and Molecular Genomics
  • Medical director, Molecular Genomics Laboratory, Providence St. Joseph Health Anatomic & Molecular Genetic Pathology

Brian D. Piening, PhD

Selected Works
  • Assistant member, Cancer Immuno-Genomics Laboratory
  • Technical Director, Molecular Genomics Laboratory, Providence St. Joseph Health